EP1599210A1 - Traitement combine comprenant un derive d'indolopyrrolocarbazole et un autre agent antitumoral - Google Patents

Traitement combine comprenant un derive d'indolopyrrolocarbazole et un autre agent antitumoral

Info

Publication number
EP1599210A1
EP1599210A1 EP04711372A EP04711372A EP1599210A1 EP 1599210 A1 EP1599210 A1 EP 1599210A1 EP 04711372 A EP04711372 A EP 04711372A EP 04711372 A EP04711372 A EP 04711372A EP 1599210 A1 EP1599210 A1 EP 1599210A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutically acceptable
edotecarin
cancer
acceptable salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04711372A
Other languages
German (de)
English (en)
Inventor
Marina Ciomel
Enrico Pesenti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia Italia SpA
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia SpA, Pharmacia and Upjohn SpA filed Critical Pharmacia Italia SpA
Publication of EP1599210A1 publication Critical patent/EP1599210A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the field of the neoplastic diseases therapy.
  • this invention relates to a method for treating cancer in a subject in need of such a treatment, said method comprising the administration to the patient of a therapeutically effective amount of an indolopyrrolocarbazole derivative together with another antitumor agent.
  • the present invention further relates to pharmaceutical compositions and packaging units, which comprise an indolopyrrolocarbazole derivative and another antitumoral agent.
  • Cancer is one of the major causes of death in humans and animals; surgery, radiation and chemotherapy are the useful means to fight cancer.
  • combined chemotherapy designed to treat cancer using more than one drug in combination or in association, is a well-known modality to optimise the treatment regimen of neoplastic diseases .
  • the present invention meets this need by providing a pharmaceutical combination comprising an indolopyrrolocarbazole derivative,- i.e. edotecarin or a pharmaceutically acceptable salt thereof and another antitumor agent chosen between docetaxel and capecitabine .
  • a combined preparation for simultaneous, separate or sequential use in cancer treatment comprising a pharmaceutical composition comprising edotecarin or a pharmaceutically acceptable salt thereof and at least a pharmaceutically acceptable excipient and a pharmaceutical composition comprising docetaxel and at least a pharmaceutically acceptable excipient.
  • a further object of the present invention is a combined preparation for simultaneous, separate or sequential use in cancer treatment, comprising a pharmaceutical composition comprising edotecarin and at least a pharmaceutically acceptable excipient and a pharmaceutical composition comprising capecitabine and at least a pharmaceutically acceptable excipient.
  • Edotecarin (CAS RN 174402-32-5), i.e. 12- ⁇ -D- glucopyranosyl-2, 10-dihydroxy-6- ⁇ [2-hydroxy-l- hydroxymethyl) ethyl] amino ⁇ -12, 13-dihydro-6H-indolo [2,3- a]pyrrole [3, 4-c] carbazole-5, 7-dione, is an indolopyrrolocarbazole derivative also known as ED-749 or J-107088 having the following formula:
  • Edotecarin can be prepared, for example, according to the method described in the European Patent no. 545,195, in the European patent application No. 95917506 both to Banyu Pharm. CO. LTD., or in Tetrahedron (2001) 57, 8917-23.
  • edotecarin can be present in the form of a pharmaceutically acceptable salt.
  • a pharmaceutically acceptable salt is, according to the present invention, any salt of acid or basic addition which maintains the biological effectiveness and the properties of edotecarin and which is formed by a suitable non toxic acid or base.
  • pharmaceutically acceptable salts of addition with acids both with inorganic acids, such as hydrochloric and methansulfonic acid and with organic acids, such as acetic, citric, tartaric and maleic acid.
  • Capecitabine can be prepared, for example, following the methods described in the European patent No. 602,454 and US patent No. 5,472,949, both to Hoffmann- La Roche .
  • Capecitabine is commercially available as XELODA ® .
  • Docetaxel (CAS RN 114977-28-5) having the following formula:
  • Docetaxel is a synthetic derivative of paclitaxel, developed and launched by Aventis Pharma.
  • the preparation of docetaxel is described, for example, in the European Patents No. 253,738 and 253,739 and in the International patent application WO 92/09589, all to Rhone-Poulenc .
  • Docetaxel is commercially available as TAXOTERE ® .
  • treating or “to treat” mean to alleviate symptoms, eliminate the causation either on a temporary or permanent basis, or to prevent or slow the appearance of symptoms.
  • treatment includes, according to the present invention, alleviation, elimination, of the cause and prevention of the cancer.
  • these combinations are also useful for the treatment of other mammals, among them horses, dogs, cats, mice, ovines, swine, etc.
  • the combined preparations according to the present invention can be used in cancer treatment.
  • cancer includes all types of cancer, as those listed in the National Cancer Institute (NCI) Web Site, at the following Internet address: http: //www.nci .nih.gov/cancerinfo/types/ and comprises, for instance, breast cancer, colon cancer, colorectal cancer, liver cancer, pancreatic cancer, renal cancer, uterine cancer, head and neck cancer, brain cancer, ovarian cancer, prostate cancer, testicular cancer, kidney cancer, lung cancer, stomach cancer, oesophageal cancer, bladder cancer, bone cancer, skin cancer, limphoma, malignant melanoma, neuroblastoma, glioma, multiform glioblastoma and the like.
  • NCI National Cancer Institute
  • terapéuticaally-effective is intended to qualify the amount of each agent for use in the combination therapy, which will achieve the goal of improvement in disease severity and the frequency of incidence over treatment of each agent by itself, and/or of amelioration of adverse side effects typically associated with alternative therapies.
  • the administration of the constituents of the combined preparation according to the present invention can be made simultaneously, separately or sequentially in any order.
  • the present invention intends to embrace administration of edotecarin or a pharmaceutically acceptable salt thereof with capecitabine or docetaxel in a sequential manner in a regimen that will provide beneficial effects of the drug combination, and intends as well to embrace co-administration of these agents in a substantially simultaneous manner, such as in a single dosage unit having a fixed ratio of these active agents or in multiple, separate dosage units for each agent, where the separate dosage units can be taken together contemporaneously, or taken within a period of time sufficient to receive a beneficial effect from both of the constituents of the combination.
  • edotecarin or of a pharmaceutically acceptable salt thereof and of capecitabine in the preparation of a medicament for use against cancer, wherein edotecarin or a pharmaceutically acceptable salt thereof and capecitabine are administered simultaneously, separately or sequentially.
  • the constituents of the combined preparation according to the present invention can be administered to the patient in any manner that is medically acceptable from the medical viewpoint, including orally, parenterally and with loco-regional therapeutic approaches, such as implants .
  • Oral administration includes the administration of the constituents of the combined preparation according to the invention in a suitable pharmaceutical form for oral use, such as tablets, capsules, suspensions, solutions, emulsions, powders, granules, syrups and the like.
  • Parenteral administration includes the administration of the constituents of the combined preparation according to the invention in a suitable pharmaceutical form for sub-cutaneous, intramuscular or intravenous use.
  • Implants include, for example, intrarterial implants .
  • edotecarin or a pharmaceutically acceptable salt thereof may be administered in a suitable pharmaceutical form for intravenous use
  • docetaxel may be administered in a suitable pharmaceutical form for intravenous use
  • capecitabine may be administered in a suitable pharmaceutical form for oral use.
  • the selection of the route, of the dosage, of the time interval and of the order of administration of the constituents of the combined preparation according to the present invention can be determined by a person skilled in the medical art. Such selection can vary, inter alia, according to the particular pharmaceutical composition of edotecarin or of a pharmaceutically acceptable salt thereof which is used, according to the particular pharmaceutical composition of capecitabine which is used or according to the particular pharmaceutical composition of docetaxel which is used, on the type, severity and extension of the cancer being treated, on the sex, age, and on the particular clinical conditions of the patient at the time of the treatment.
  • a pharmaceutical composition is formed.
  • Said pharmaceutical composition which therefore comprises edotecarin or a pharmaceutically acceptable salt thereof and capecitabine or docetaxel as active agents, a carrier or a pharmaceutically acceptable excipient, is suitable for treating cancer.
  • a pharmaceutical composition which comprises edotecarin or a pharmaceutically acceptable salt thereof and capecitabine or docetaxel as active agents, and at least a carrier or a pharmaceutically acceptable excipient, for cancer treatment.
  • compositions can usually contain, for instance, pharmaceutically acceptable salts, buffering agents, preservatives and/or compatible carriers .
  • pharmaceutically acceptable carrier refers herein to one or more conventional compatible solid or liquid filling agents, diluting substances or encapsulating substances which are suitable for administration to mammals, among them humans.
  • compositions suitable for parenteral administration are formulated in a sterile form.
  • the amount of active ingredient contained in the aforesaid pharmaceutical compositions according to the present invention may vary, depending quite amply on many factors such as the route of administration and the vehicle; for example, a single dosage unit may contain from 0.5 to 500 mg of edotecarin or a pharmaceutically acceptable salt thereof and from 10 to 1,000 mg of capecitabine or from 1 mg to 100 mg of docetaxel .
  • a further aspect of the present invention relates to a method for the treatment of cancer, which comprises administering to a mammal a therapeutically effective amount of edotecarin or of a pharmaceutically acceptable salt thereof and capecitabine, in amounts effective to produce a synergistic anti-cancer effect.
  • the present invention relates to a method for treating a cancer in a patient in need thereof, said method comprising the administration to said patient of edotecarin or a pharmaceutically acceptable salt thereof and of capecitabine, in amounts effective to produce a synergistic anti-cancer effect.
  • Yet another aspect of the present invention relates to a method for the treatment of cancer, which comprises administering to a mammal a therapeutically effective amount of edotecarin or of a pharmaceutically acceptable salt thereof and docetaxel, in amounts effective to produce a synergistic anti-cancer effect.
  • the present invention relates to a method for treating a cancer in a patient in need thereof, said method comprising the administration to said patient of edotecarin or a pharmaceutically acceptable salt thereof and of docetaxel, in amounts effective to produce a synergistic anti-cancer effect.
  • a synergistic anti-cancer effect refers to a greater than additive anti-cancer effect which is produced by a combination of two active and which exceeds that which .would otherwise results from individual administration of either active alone.
  • the amount of edotecarin or a pharmaceutically acceptable salt thereof together with the amount of capecitabine or docetaxel constitute an amount effective for the treatment of cancer.
  • the administration of edotecarin or of a pharmaceutically acceptable salt thereof can vary from about 0.1 mg/m 2 to about 100 mg/m 2 per body surface area of an adult, preferably from about 10 mg/m 2 to about 50 mg/m 2 per body surface area of an adult.
  • the administration of capecitabine can vary from about 10 mg/m 2 to about 10000 mg/m 2 per body surface area of an adult, preferably from about 500 mg/m 2 to about 2500 mg/m 2 per body surface area of an adult.
  • the administration of docetaxel can vary from about 0.5 mg/m 2 to about 500 mg/m 2 per body surface area of an adult, preferably from about 10 mg/m 2 to about 100 mg/m 2 per body surface area of an adult.
  • the present invention also provides a therapeutic kit which comprises, in suitable packaging units, a pharmaceutical composition comprising edotecarin or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising capecitabine or docetaxel, present within individual packaging units or within distinct packaging units .
  • kits according to ⁇ the invention comprises a pharmaceutical composition comprising edotecarin or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising capecitabine or docetaxel, within distinct packaging units .
  • kits according to the invention are intended for use in anti-cancer therapy, as defined above.
  • Edotecarin 3 mg/Kg was administered intravenously on day 9 and 16;
  • Docetaxel 5 mg/Kg was administered intravenously on day
  • Tumour measurements were taken by a calliper 1-2 times a week. These tumor measurements were converted to mg tumor weight by following formula:
  • Antitumor response to the actives alone or in combination was also assessed by evaluating the tumor growth delay, namely the time taken by the tumours of the different treatment groups to reach the predetermined weight of (1 g) (T-C) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne un procédé de traitement du cancer chez un sujet nécessitant un tel traitement. Ce procédé consiste à administrer au patient une dose efficace sur le plan thérapeutique d'édotécarine avec de la capécitabine ou du docetaxel.
EP04711372A 2003-02-21 2004-02-16 Traitement combine comprenant un derive d'indolopyrrolocarbazole et un autre agent antitumoral Withdrawn EP1599210A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI20030317 2003-02-21
IT000317A ITMI20030317A1 (it) 2003-02-21 2003-02-21 Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
PCT/EP2004/050130 WO2004073719A1 (fr) 2003-02-21 2004-02-16 Traitement combine comprenant un derive d'indolopyrrolocarbazole et un autre agent antitumoral

Publications (1)

Publication Number Publication Date
EP1599210A1 true EP1599210A1 (fr) 2005-11-30

Family

ID=32894164

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04711372A Withdrawn EP1599210A1 (fr) 2003-02-21 2004-02-16 Traitement combine comprenant un derive d'indolopyrrolocarbazole et un autre agent antitumoral

Country Status (10)

Country Link
EP (1) EP1599210A1 (fr)
JP (1) JP2006518355A (fr)
AR (1) AR043241A1 (fr)
BR (1) BRPI0407642A (fr)
CA (1) CA2516097A1 (fr)
CL (1) CL2004000319A1 (fr)
IT (1) ITMI20030317A1 (fr)
MX (1) MXPA05008879A (fr)
TW (1) TW200500073A (fr)
WO (1) WO2004073719A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007307080B2 (en) * 2006-10-06 2014-01-09 Bavarian Nordic A/S Methods for treating cancer with MVA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
EE200200471A (et) * 2000-02-28 2003-12-15 Aventis Pharma S.A. Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004073719A1 *

Also Published As

Publication number Publication date
ITMI20030317A1 (it) 2004-08-22
AR043241A1 (es) 2005-07-20
WO2004073719A1 (fr) 2004-09-02
BRPI0407642A (pt) 2006-03-01
MXPA05008879A (es) 2005-10-05
TW200500073A (en) 2005-01-01
CA2516097A1 (fr) 2004-09-02
JP2006518355A (ja) 2006-08-10
CL2004000319A1 (es) 2005-04-22

Similar Documents

Publication Publication Date Title
JP7305613B2 (ja) 併用がん療法
EP3066101B1 (fr) Polythérapie pour le traitement du cancer utilisant des inhibiteurs de protéine à bromodomaine et à domaine extra-terminal (bet)
US6667337B2 (en) Combination therapy for cancer
JP2012500180A5 (fr)
Ajani et al. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma
MXPA01010138A (es) Docetaxel en combinacion con rhumas her2 para el tratamiento de canceres.
JP2014132009A5 (fr)
KR20160023816A (ko) 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
JP2002507571A (ja) アントラサイクリン誘導体とカンプトテシン誘導体の相乗組合せを含有する抗腫瘍組成物
JP2003533485A5 (fr)
JP2009536956A (ja) 抗癌治療法
CA2714608A1 (fr) Combinaison comprenant du paclitaxel destinee au traitement du cancer des ovaires
KR20130118981A (ko) 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물
JP2019508433A (ja) Ｌｉｖ１−ａｄｃ及び化学療法剤を用いた併用療法
JP2706371B2 (ja) 癌治療用補助剤及びそれを用いたキット
US6562834B2 (en) Combination comprising camptothecin and a stilbene derivative for the treatment of cancer
WO2004073719A1 (fr) Traitement combine comprenant un derive d'indolopyrrolocarbazole et un autre agent antitumoral
TW201306833A (zh) 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合
US20210315898A1 (en) Combination therapy for treating cancer
KR20210150470A (ko) A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용
JP2021533107A (ja) 癌を治療するための併用療法
ZA200508696B (en) Use of irinotecan for treatment of resistant breast cancer
US20230029336A1 (en) Combination Therapy for Treating a Hematological Malignancy
WO2008135792A1 (fr) Composés pm00104 utilisés en thérapie anticancéreuse
WO2021224381A1 (fr) Polythérapie pour le traitement du cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050921

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PFIZER ITALIA S.R.L.

17Q First examination report despatched

Effective date: 20071227

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090330